较低危骨髓增生异常综合征的诊治进展  

Progress in the diagnosis and treatment of lower-risk myelodysplastic syndrome

作　　者：丁宇斌 唐玉凤[2] 唐旭东[3] DING Yubin;TANG Yufeng;TANG Xudong(Graduate School,China Academy of Chinese Medical Sciences,Beijing100700,China;Department of Laboratory,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing100091,China;Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing100091,China)

机构地区：[1]中国中医科学院研究生院,北京100700 [2]中国中医科学院西苑医院检验科,北京100091 [3]中国中医科学院西苑医院血液科,北京100091

出　　处：《中国医药导报》2020年第31期40-44,共5页China Medical Herald

基　　金：国家自然科学基金面上项目(81673819);国家中医药管理局中医药行业科研专项项目(201507001-13)。

摘　　要：较低危骨髓增生异常综合征(MDS)是使用预后积分系统进行定义的,纳入分子学异常有助于提高该系统危险分层的判断精准度。针对较低危MDS不同的外周血细胞减少,可以考虑选择促红细胞生成素类似物(促红细胞生成刺激剂、Darbepoetin-α)、转化生长因子-β(TGF-β)通路阻断剂luspatercept、来那度胺用于改善MDS的贫血,罗米司亭和艾曲波帕用于治疗MDS的血小板减少症,去甲基化药物和抗胸腺细胞球蛋白用于治疗MDS的全血细胞减少症,以及临床试验中的多种新药针对特定基因突变的信号通路进行治疗。本文就较低危MDS的诊治进展进行综述,以期抛砖引玉,指导临床治疗。The lower-risk myelodysplastic syndrome(MDS)is defined by the prognostic scoring system,and the inclusion of molecular abnormalities is conducive to the accuracy of risk stratification of the system.In view of the peripheral blood cytopenia of lower-risk MDS,erythropoietin analogues(erythropoiesis-stimulating agents,darbepoetin-α),transforming growth factor-β(TGF-β)pathway blockers(luspatercept)and Lenalidomide can be selected to improve the anemia of MDS,Romiplostim and Eltrombopag are used for thrombocytopenia,demethylation drugs and antithymocyte globulin ameliorate pancytopenia of MDS,and many new drugs in clinical trials are intended for the signaling pathway of specific gene mutation.In this paper,the diagnosis and treatment of low-risk MDS are reviewed in order to guide the clinical treatment.

关 键 词：较低危 骨髓增生异常综合征 治疗策略 临床试验 

分 类 号：R551.3[医药卫生—血液循环系统疾病]